Hosted on MSN2mon
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal
Investing.com -- Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending ...
pharmaphorum7d
Kite and Sangamo come together in $3bn cancer gene editing alliance
Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...
Business Wire2mon
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics ...